Tech Transfer eNews Blog
Industry-Sponsored Research Management sample issue

U of Edinburgh start-up gets £500k investment to develop its life-saving technology for dialysis patients


By Jesse Schwartz
Published: May 9th, 2018

A University of Edinburgh start-up has secured a £500,000 ($675K US) investment for its technology that may reduce the risk of cardiovascular disease among patients undergoing long-term dialysis.

Invizius received the funding from Mercia Fund Managers in the first investment deal since Mercia partnered with the University of Edinburgh in November 2017. The funds will allow Invizius to grow its team and develop the technology in preparation for clinical trials.

Cardiovascular disease is the leading cause of death for dialysis patients. This is because the patient’s immune system sees the dialysis filter as a foreign body and creates inflammation that, over time, severely damages the cardiovascular system.

Invizius’ H-Guard product is an anti-inflammatory that coats the filter’s surface to make it seem less foreign to the patient’s immune system. The technology is especially promising given that, unlike other proposed solutions, it does not shut down the immune system but rather tricks it into accepting the dialysis filter.

The start-up has received support from Edinburgh Innovations, the university’s commercialization arm, as well as Scottish Enterprise, which supports the country’s innovation and economic development activity.

“I’m delighted to see this substantial investment in a university spinout company whose work holds such promise for many patients,” says George Baxter, CEO of Edinburgh Innovations. “It’s a perfect example of how partnerships can enhance the university’s impact, and Edinburgh Innovations looks forward to working with Mercia and our researchers to identify and support further such opportunities.”

Nicola Broughton, head of universities at Mercia, comments, “Invizius builds on the world-class research carried out at the University of Edinburgh and is an excellent choice for our first investment under our partnership with the university. This technology could revolutionize kidney dialysis and, with 3 million patients worldwide, has the potential to save countless lives. The funding will take the company one step closer to bringing it to market.”

Source: SBNN

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment